A brand new class of epilepsy medicines primarily based on an ingredient derived from marijuana might be accessible as quickly as within the second half of 2018 within the United States pending Food and Drug Administration approval.

Officials from GW Pharmaceuticals, the corporate that developed the drug, on Wednesday introduced promising outcomes from a research on 171 sufferers randomized into remedy and placebo teams.

Members of the group, who have been 2 to 55 years of age, have a situation known as Lennox-Gastaut Syndrome and have been affected by seizures that weren’t being managed by current medication. 

Click here to read the complete article

MagNerd.com via 420Intel.com

Recent News Articles

Monday March 25

Greater Boston's First Pot Shop Opening Weekend Goes 'According To Plan' - Cannabis News

in Cannabis News

by Bruce Kennedy - Editor in Chief

Brookline can now be added to the short list of Massachusetts cities and towns where…

1296 hits

Monday March 25

CVS to sell CBD products in 800 stores in 8 states - Cannabis News

in Finance

by Bruce Kennedy - Editor in Chief

CBD-infused sprays, roll-ons, creams and salves will be offered as an 'alternative source of relief'.

1163 hits

Monday March 25

Nearly Half of Anxiety Patients Find Medical Marijuana More Effective Than Pills - Cannabis News

in Medical News

by Bruce Kennedy - Editor in Chief

A new study shows that people suffering from anxiety may be able to successfully transition…

1158 hits

Monday March 25

Utah is looking for software to run its medical cannabis program - Cannabis News

in Hi-Tech

by Bruce Kennedy - Editor in Chief

The state has started its search for multimillion-dollar software that will form the spine of…

1104 hits

Tuesday March 26

Hemp About To Be Removed From Texas’ Controlled Substances List - Cannabis News

in Law & Crime

by Bruce Kennedy - Editor in Chief

The state of Texas is taking a big step toward legitimizing the use of CBD…

828 hits